TKM-011 (Humanized anti-CD20 antibody)
- A potent cytotoxic effects against Rituximab-resistant lymphoma cells.
- Unique epitope not shared with Rituximab.
![](https://www.tokumen.co.jp/wp/wp-content/themes/iij_custom/images/pages/img_d3_07_01en.png)
FIH Test of TKN-011 for Lymphoma Patients
- The phase I study was done in two hospitals in Japan.
- No dose-limiting toxicities, related serious adverse events were observed.
- Effective for almost all patients with relapsed or refractory non-Hodgkin’s lymphoma.
![](https://www.tokumen.co.jp/wp/wp-content/themes/iij_custom/images/pages/img_d3_07_02en.png)
Rationale of B-cell Depletion Therapy for PBC*
- The autoantibodies and autoreactive CTL are involved in PBC pathogenesis.
- B-cell depletion therapy can provide better outcome in patients with PBC like RA and MS.
![](https://www.tokumen.co.jp/wp/wp-content/themes/iij_custom/images/pages/img_d3_07_04en.png)